NCT04053647

Brief Summary

Persistent hypoparathyroidism is an underestimate but major complication of total thyroidectomy. The hypothesis of the investigators is that the mental health is impaired in hypoparathyroid patients compared with thyroidectomized patients without hypoparathyroidism. The investigators evaluated the quality of life using the SF-36 survey in comparison with a control population of patients thyroidectomized but free from this complication. The voice quality, the cardiovascular risk, the kidney function and the incidence of urinary lithiasis were also evaluated.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
143

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2020

Shorter than P25 for all trials

Geographic Reach
1 country

6 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 22, 2019

Completed
3 months until next milestone

First Posted

Study publicly available on registry

August 12, 2019

Completed
6 months until next milestone

Study Start

First participant enrolled

February 5, 2020

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 24, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 24, 2020

Completed
Last Updated

August 7, 2020

Status Verified

August 1, 2020

Enrollment Period

5 months

First QC Date

May 22, 2019

Last Update Submit

August 6, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Mental health

    Items from mental quality of life score defined by the SF36 (Short Form 36) survey

    Through study completion, an average of 1 year

Secondary Outcomes (6)

  • Physical quality score

    Through study completion, an average of 1 year

  • Global quality of life score

    Through study completion, an average of 1 year

  • Voice quality

    Through study completion, an average of 1 year

  • Renal function quality

    Through study completion, an average of 1 year

  • Presence of urinary lithiasis

    Through study completion, an average of 1 year

  • +1 more secondary outcomes

Study Arms (2)

Hypoparathyroid patients

Patients with persistent hypoparathyroidism after total thyroidectomy, defined as serum PTH inferior to 15 pg/mL 6 months after surgery and the need of vitamin-calcic supplementation.

Other: Non-interventional study

Control patients, without hypoparathyroidism

Other: Non-interventional study

Interventions

Non-interventional study

Control patients, without hypoparathyroidismHypoparathyroid patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The study population is that of hypoparathyroid patients of the Hypoparathyroidism France combination who have undergone total thyroidectomy and who have agreed to participate in the study. Patients with permanent hypoparathyroidism who were included in the ThyrQol study and in the FOTHYR study will also be solicited. Endocrinologists at the University Hospital of Nantes also have patients with permanent hypoparathyroidism in their patients. The control population consists of patients who had a total thyroidectomy and were included in the ThyrQol study between 2014 and 2018, without sequelary hypoparathyroidism.

You may qualify if:

  • Patients operated of total thyroidectomy
  • Patients suffering from persistent hypoparathyroidism defined as serum PTH inferior to 15 pg/mL 6 months after the surgery, requiring vitamin-calcic supplementation.
  • Age superior to 18
  • Answering the survey

You may not qualify if:

  • Pregnancy at the time of the study
  • Age inferior to 18 or adult under guardianship
  • Patients with vitamino-calcic supplementation without serum PTH measurement
  • Cause of hypoparathyroidism other than post-operatory.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (6)

CHU Angers

Angers, 49100, France

Location

Centre Hospitalier Le Mans

Le Mans, 72037, France

Location

CHU Limoges

Limoges, 87042, France

Location

CHU Nancy

Nancy, 54511, France

Location

CHU Nantes

Nantes, 44000, France

Location

AP-HP La Pitié Salpétrière

Paris, 75013, France

Location

MeSH Terms

Conditions

Hypoparathyroidism

Condition Hierarchy (Ancestors)

Parathyroid DiseasesEndocrine System Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 22, 2019

First Posted

August 12, 2019

Study Start

February 5, 2020

Primary Completion

June 24, 2020

Study Completion

June 24, 2020

Last Updated

August 7, 2020

Record last verified: 2020-08

Locations